CombiGene AB (publ) (STO:COMBI)

Market Cap	47.72M
Revenue (ttm)	2.00M
Net Income (ttm)	-44.88M
Shares Out	19.80M
EPS (ttm)	-2.27
PE Ratio	n/a
Forward PE	n/a
Dividend	0.20 (8.00%)
Ex-Dividend Date	Jun 13, 2025

Volume	5,606
Average Volume	11,206
Open	2.550
Previous Close	2.500
Day's Range	2.410 - 2.600
52-Week Range	1.270 - 4.120
Beta	1.22
RSI	51.21
Earnings Date	Aug 22, 2025

About CombiGene AB

CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorpor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 9
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: COMBI

Financial Performance

In 2024, CombiGene AB's revenue was 2.00 million, a decrease of -71.47% compared to the previous year's 7.01 million. Losses were -44.88 million, 25.8% more than in 2023.